Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adept is a 4% icodextrin solution, a cornstarch-derived, water-soluble branched glucose polymer. It is administered intraperitoneally as an adjunct to good surgical technique for the reduction of post-surgical adhesions, primarily in gynecological laparoscopic adhesiolysis. Its mechanism involves hydroflotation, where its colloidal osmotic action retains fluid in the peritoneal cavity for 3-4 days, creating a physical barrier between traumatized surfaces to minimize tissue apposition during healing. Adept was approved by the FDA in 2006 for gynecological laparoscopic adhesiolysis and by the European Union in 1999 as a medical device to reduce adhesions after abdominal surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Adept.